S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

LXEO Lexeo Therapeutics Inc

14.89

0.87 (6.21%)

Jul 03 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Lexeo Therapeutics (NASDAQ:LXEO)
Historical Stock Chart
From Jun 2024 to Jul 2024

Click Here for more Lexeo Therapeutics Charts.

Lexeo Therapeutics (NASDAQ:LXEO)
Historical Stock Chart
From Jul 2023 to Jul 2024

Click Here for more Lexeo Therapeutics Charts.

Lexeo Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Friday 14 June 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 12 June 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Wednesday 22 May 2024 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 14 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Monday 13 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Thursday 9 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 9 May 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 9 May 2024 (2 months ago) • Edgar (US Regulatory)

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Thursday 9 May 2024 (2 months ago) • GlobeNewswire Inc.

Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Tuesday 7 May 2024 (2 months ago) • GlobeNewswire Inc.

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Monday 22 April 2024 (2 months ago) • GlobeNewswire Inc.

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Tuesday 16 April 2024 (3 months ago) • GlobeNewswire Inc.

More Lexeo Therapeutics Inc News Articles

Cann American (CE)

Ocean Power Technologies

1812 Brewing (PK)

Net Savings Link (PK)

Seafarer Exploration (PK)

Voip Pal Com (QB)

Enzolytics (PK)

Bell Buckle (PK)

Digital Brand Media and ... (PK)

Virexit Technologies (PK)

Branded Legacy (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions